Avantor Results Presentation Deck

Q3 highlights Strong business momentum Ongoing core business growth led by Biopharma COVID-19 tailwinds in line with guidance, driven by vaccine contributions Significant margin expansion and adjusted EPS growth Executing on our growth strategy Announced intent to acquire Masterflex, expanding our proprietary single-use offering for critical bioproduction workflows Continued investments in capabilities and capacity Launched handheld gene sequencer from Oxford Nanopore Technologies - Looking ahead Continued strong business momentum, driven by Biopharma and a growing order book Increased full year guidance to reflect latest projection 2022 planning underway - expect to be in line with long-term objectives - avantor™ 5 3

View entire presentation